GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aligos Therapeutics Inc (NAS:ALGS) » Definitions » Price-to-Owner-Earnings

ALGS (Aligos Therapeutics) Price-to-Owner-Earnings : (As of Mar. 27, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Aligos Therapeutics Price-to-Owner-Earnings?

As of today (2025-03-27), Aligos Therapeutics's share price is $9.35. Aligos Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Aligos Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


ALGS's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.73
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-03-27), Aligos Therapeutics's share price is $9.35. Aligos Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-20.90. Therefore, Aligos Therapeutics's PE Ratio (TTM) for today is At Loss.

As of today (2025-03-27), Aligos Therapeutics's share price is $9.35. Aligos Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-20.90. Therefore, Aligos Therapeutics's PE Ratio without NRI for today is At Loss.


Aligos Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Aligos Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aligos Therapeutics Price-to-Owner-Earnings Chart

Aligos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Aligos Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aligos Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Aligos Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aligos Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Aligos Therapeutics's Price-to-Owner-Earnings falls into.


;

Aligos Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Aligos Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=9.35/-21.41
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aligos Therapeutics  (NAS:ALGS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Aligos Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Aligos Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Aligos Therapeutics Business Description

Traded in Other Exchanges
Address
One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Executives
Roche Finance Ltd 10 percent owner C/O HOFFMAN LA ROCHE, 124 GRENSACHERSTRASSE CH 4002, BASEL SWITZERLAND V8
Roche Holding Ltd 10 percent owner ROCHE HOLDING, LTD., GRENZACHERSTRASSE 124, BASEL V8 CH-4070
Carole Nuechterlein director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Matthew W. Mcclure officer: Chief Medical Officer C/O ALIGOS THERAPEUTICS, INC., 1 CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
James Paul Scopa director 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Thomas Woiwode director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Vivo Capital Surplus Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Julian A. Symons officer: See Remarks C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Leonid Beigelman director, officer: President C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Lucinda Y. Quan officer: See Remarks C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Lawrence Blatt director, officer: Chief Executive Officer